Efficacy and safety of infliximab in patients with autoimmune hepatitis

• Type: Article in International Scientific Journal
• Date: 2024

Authors

Efe, C (Author) Other; Lytvyak, E (Author) Other; Eskazan, T (Author) Other; Liberal, R (Author) Other; Androutsakos, T (Author) Other; Gökçe, DT (Author) Other; Beretta-Piccoli, BT (Author) Other; Janik, M (Author) Other; Bernsmeier, C (Author) Other; Arvaniti, P (Author) Other; Milkiewicz, P (Author) Other; Batibay, E (Author) Other; Yüksekyayla, O (Author) Other; Ergenç, I (Author) Other; Arikan, Ç (Author) Other; Stättermayer, AF (Author) Other; Barutcu, S (Author) Other; Cengiz, M (Author) Other; Gül,Ö (Author) Other; Heurgue, A (Author) Other; Heneghan, MA (Author) Other; Verma, S (Author) Other; Purnak, T (Author) Other; Törüner, M (Author) Other; Kayhan, MA (Author) Other; Hatemi, I (Author) Other; Zachou, K (Author) Other; Macedo G (Author) FMUP; Drenth, JPH (Author) Other; Björnsson, E (Author) Other; Montano-Loza, AJ (Author) Other; Wahlin, S (Author) Other; Higuera-de la Tijera, F (Author) Other

Journal

Title: Hepatology

ISSN: 0270-9139

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-017-30X

DOI: 10.1097/hep.0000000000001089

Abstract (EN): Background and Aims: A limited number of drugs are used as standard or alternative therapies in autoimmune hepatitis (AIH). No specific recommendations are available for patients failing to respond to these therapies. We analyzed the efficacy and safety of infliximab in patients with AIH. Approach and Results: We performed a retrospective study of 42 patients with AIH who received infliximab at 21 liver centers in 12 countries. Patients were categorized according to the reason for infliximab therapy. Patients in group 1 (n=20) had failed standard, second-line (mycophenolate mofetil and 6-mercaptopurine) or third-line (tacrolimus or cyclosporine) therapy. In group 2 (n=22), infliximab was given for treatment of concomitant extrahepatic autoimmune diseases. Patients received a median of 17 (range: 3-104) infliximab infusions. Complete biochemical response (CR) was achieved or maintained in 33 (78%) patients during infliximab therapy. In group 1, infliximab induced CR in 11 of 20 (55%) patients. In group 2, 16 patients with CR prior to infliximab maintained remission, and the remaining 6 patients with active AIH (5 on standard and 1 on both second-line and third-line therapy) showed CR following infliximab therapy. Infliximab led to CR in 75% (6/8) of nonresponders to second-line and in 46% (6/13) of failing third-line therapy. Overall, 65% (17/26) of the patients with active AIH achieved CR on infliximab. Infliximab was discontinued in 3 patients of group 1. One patient had a severe allergic reaction and 2 developed anti-infliximab autoantibodies. Conclusions: Our study suggests that infliximab may be an effective and safe rescue therapy in AIH.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 12